Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Nerdwallet Inc (NRDS) vs Viatris Inc (VTRS) Price & Performance

Nerdwallet IncTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Nerdwallet Inc vs Viatris Inc — how do they compare? Nerdwallet Inc trades at $9.41 (market cap $610.79M), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Viatris Inc is far larger — about 31.3× Nerdwallet Inc's market cap, and Viatris Inc pays a 2.89% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals.

NRDSVTRS
Market Cap
$610.79M$19.09B
Sector
FinancialsHealth
52-Week High
$15.93$17.86
52-Week Low
$7.58$9.49
Enterprise Value
$525.09M$31.21B
Dividend Yield
2.89%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Nerdwallet Inc

NRDS trades at $9.56, down 3.24% amid bearish technical signals, though fundamentals show strong improvement with revenue growing from $539M in 2022 to $837M in 2025 and net income turning positive. The stock appears undervalued with a P/E of 10.62 and P/S of 0.79, while analyst sentiment remains positive with 4 out of 6 ratings being Buy. Recent Q2 2026 earnings missed expectations but management highlights an inflection point in business operations.

The outlook is mixed: strong profitability metrics (93.5% gross margin, 18.16% ROE) and analyst price targets suggesting 27.9% upside support bullish case, but technical weakness and competitive pressures in credit card/search segments pose near-term risks. Execution on Q3 guidance and sustained cash flow generation will be critical for stock performance.

Viatris Inc

Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.

The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Nerdwallet Inc

Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.

Read more on NRDS

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS